Skip to main content
SpringerLink
Log in

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The dipeptidyl peptidase-4 inhibitor vildagliptin (Galvus®) is approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. A fixed-dose combination of vildagliptin/metformin (Eucreas®) is also available. This article reviews the clinical efficacy and tolerability of vildagliptin in the treatment of type 2 diabetes, as well as summarizing its pharmacological properties. Results of randomized controlled trials demonstrated that oral vildagliptin improved glycaemic control when administered as monotherapy, as dual therapy in combination with metformin, a sulfonylurea or a thiazolidinedione, as triple therapy in combination with metformin plus a sulfonylurea, and in combination with insulin with or without metformin. Improvements in glycaemic control were also seen with vildagliptin in elderly patients with type 2 diabetes and in patients with type 2 diabetes and moderate or severe renal impairment. Vildagliptin was generally well tolerated in patients with type 2 diabetes, was weight neutral and was associated with a low risk of hypoglycaemia, reflecting its glucose-dependent mechanism of action. Thus, oral vildagliptin is a useful option as monotherapy or as add-on therapy for patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

    PubMed  CAS  Google Scholar 

  2. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.

    PubMed  CAS  Google Scholar 

  3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.

    PubMed  CAS  Google Scholar 

  4. European Medicines Agency. Galvus (vildagliptin): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Accessed 4 Nov 2013.

  5. European Medicines Agency. Eucreas (vildagliptin/metformin): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000807/WC500030594.pdf. Accessed 4 Nov 2013.

  6. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(8):675–82.

    PubMed  CAS  Google Scholar 

  7. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–5.

    PubMed  CAS  Google Scholar 

  8. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166–74.

    PubMed  CAS  Google Scholar 

  9. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047–56.

    PubMed  CAS  Google Scholar 

  10. Ahrén B, Pacini G, Foley JE, et al. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28(8):1936–40.

    PubMed  Google Scholar 

  11. Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther. 2013;4(2):431–42.

    PubMed Central  PubMed  Google Scholar 

  12. Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27(12):2874–80.

    PubMed  Google Scholar 

  13. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7(6):692–8.

    PubMed  CAS  Google Scholar 

  14. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132–8.

    PubMed  CAS  Google Scholar 

  15. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39(3):218–23.

    PubMed  CAS  Google Scholar 

  16. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114–24.

    PubMed  CAS  Google Scholar 

  17. Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83(2):233–40.

    PubMed  CAS  Google Scholar 

  18. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab. 2008;10(10):931–8.

    PubMed  CAS  Google Scholar 

  19. Forst T, Dworak M, Berndt-Zipfel C, et al. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(6):576–9.

    PubMed  CAS  Google Scholar 

  20. Filozof C, Gautier J-F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318–26.

    PubMed  CAS  Google Scholar 

  21. Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther. 2012;14(6):475–84.

    PubMed  CAS  Google Scholar 

  22. Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother. 2012;13(18):2581–91.

    PubMed  CAS  Google Scholar 

  23. Azuma K, Rádiková Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(2):459–64.

    PubMed  CAS  Google Scholar 

  24. He YL, Foteinos G, Neelakantham S, et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes Metab. 2013;15(12):1111–9.

    PubMed  CAS  Google Scholar 

  25. Dalla Man C, Bock G, Giesler PD, et al. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care. 2009;32(1):14–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  26. Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730–2.

    PubMed Central  PubMed  CAS  Google Scholar 

  27. Guerci B, Monnier L, Serusclat P, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab. 2012;38(4):359–66.

    PubMed  CAS  Google Scholar 

  28. Monnier L, Colette C, Comenducci A, et al. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technol Ther. 2012;14(10):943–50.

    PubMed  CAS  Google Scholar 

  29. Sakamoto M, Nishimura R, Irako T, et al. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012;11:92.

    PubMed Central  PubMed  CAS  Google Scholar 

  30. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076–82.

    PubMed Central  PubMed  CAS  Google Scholar 

  31. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med. 2007;24(9):955–61.

    PubMed  CAS  Google Scholar 

  32. Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892–5.

    PubMed  Google Scholar 

  33. Bosi E, Dotta F, Jia Y, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506–15.

    PubMed  CAS  Google Scholar 

  34. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10(1):82–90.

    PubMed  CAS  Google Scholar 

  35. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–66.

    PubMed  CAS  Google Scholar 

  36. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab. 2010;12(8):700–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  37. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49(9):2049–57.

    PubMed  CAS  Google Scholar 

  38. Matikainen N, Taskinen M-R. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med. 2013;30(6):756–7.

    PubMed  CAS  Google Scholar 

  39. Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69(5):737–44.

    PubMed Central  PubMed  CAS  Google Scholar 

  40. van Poppel PCM, Netea MG, Smits P, et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–7.

    PubMed Central  PubMed  Google Scholar 

  41. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227(2):349–54.

    PubMed  CAS  Google Scholar 

  42. Berndt-Zipfel C, Michelson G, Dworak M, et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus: results from an exploratory study. Cardiovasc Diabetol. 2013;12:59.

    PubMed Central  PubMed  CAS  Google Scholar 

  43. Rahmi RM, Uchida AH, Rezende PC, et al. Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease. Diabetes Care. 2013;36(6):1654–9.

    PubMed  CAS  Google Scholar 

  44. McMurray JJV, Ponikowski P, Bolli GB, et al. The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD) [late-breaking abstract]. Heart Failure; 25-28 May 2013; Lisbon.

  45. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236–43.

    PubMed  Google Scholar 

  46. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175–85.

    PubMed  CAS  Google Scholar 

  47. Foley JE, Bunck MC, Möller-Goede DL, et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. 2011;54(8):1985–91.

    PubMed Central  PubMed  CAS  Google Scholar 

  48. Vardarli I, Nauck MA, Köthe LD, et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as ‘isoglycemic’ intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(4):945–54.

    PubMed  CAS  Google Scholar 

  49. Ahrén B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(5):2078–84.

    PubMed  Google Scholar 

  50. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009;94(3):846–52.

    PubMed  CAS  Google Scholar 

  51. Zografou I, Sampanis C, Papageorgiou A, et al. The combination therapy with metformin and vildagliptin decreases lymphocytes count in patients with type 2 diabetes mellitus [abstract no. 2380-PO]. Diabetes. 2012;61(Suppl 1):A600.

    Google Scholar 

  52. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007;46(7):577–88.

    PubMed  CAS  Google Scholar 

  53. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888–94.

    PubMed  CAS  Google Scholar 

  54. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249–55.

    PubMed  CAS  Google Scholar 

  55. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47(5):633–41.

    PubMed  CAS  Google Scholar 

  56. Rotondo A, Andrews CN, Depoortere I, et al. Effects of a DDP-4 inhibitor, vildagliptin, on intragastric pressure and satiation in humans [abstract no. 394]. Gastroenterology. 2013;144 (5 Suppl 1):S76.

    Google Scholar 

  57. van Poppel PCM, Gresnigt MS, Smits P, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response nor T-lymphocyte function in patients with type 2 diabetes mellitus [abstract no. 825]. Diabetologia. 2011;54(Suppl 1):S335.

    Google Scholar 

  58. Burkey BF, Russell M, Wang K, et al. Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9 [abstract no. 0788]. Diabetologia. 2006;49(Suppl 1):477–8.

    Google Scholar 

  59. Dardik B, Schwartzkopf C, Stevens D, et al. The dipeptidyl peptidase IV inhibitor NVP-LAF237 improves metabolic control in diabetic and nondiabetic cynomolgus monkeys [abstract no. 1391-P]. Diabetes. 2003;52(Suppl 1):A322.

    Google Scholar 

  60. He Y-L. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51(3):147–62.

    PubMed  CAS  Google Scholar 

  61. Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab. 2011;13(3):193–203.

    PubMed  Google Scholar 

  62. Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab. 2008;10(11):1057–61.

    PubMed  CAS  Google Scholar 

  63. Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab. 2009;11(Suppl 2):9–17.

    PubMed  CAS  Google Scholar 

  64. El-Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab. 2007;92(11):4165–71.

    PubMed  CAS  Google Scholar 

  65. Ahrén B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775–83.

    PubMed  Google Scholar 

  66. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1):14–25.

    PubMed  CAS  Google Scholar 

  67. Maeda S, Matsui T, Yamagishi S-I. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol. 2012;158(1):171–3.

    PubMed  Google Scholar 

  68. He Y-L, Zhang Y, Serra D, et al. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers. Curr Med Res Opin. 2011;27(7):1453–63.

    PubMed  CAS  Google Scholar 

  69. Novartis Pharmaceuticals. Effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure [ClinicalTrials.gov identifier NCT00894868] US National Institutes of Health, ClinicalTrials.gov 2012. http://www.clinicaltrials.gov/ct2/show/NCT00894868. Accessed 28 Jan 2014.

  70. He Y-L, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46(9):787–802.

    PubMed  CAS  Google Scholar 

  71. Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007;47(9):1152–8.

    PubMed  CAS  Google Scholar 

  72. He Y-L, Paladini S, Sabia H, et al. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int J Clin Pharmacol Ther. 2008;46(5):259–67.

    PubMed  CAS  Google Scholar 

  73. He Y-L, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin. 2008;24(6):1703–9.

    PubMed  CAS  Google Scholar 

  74. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009;37(3):536–44.

    PubMed  CAS  Google Scholar 

  75. Landersdorfer CB, He Y-L, Jusko WJ. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol. 2012;73(3):391–401.

    PubMed Central  PubMed  CAS  Google Scholar 

  76. He Y-L, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol. 2007;63(7):677–86.

    PubMed  CAS  Google Scholar 

  77. He Y-L, Kulmatycki K, Zhang Y, et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther. 2013;51(9):693–703.

    PubMed  CAS  Google Scholar 

  78. Merck Serono. Glucophage (metformin): UK summary of product characteristics. 2010. http://www.medicines.org.uk/emc/medicine/1043/SPC/Glucophage+500+mg+and+850+mg+film+coated+tablets/. Accessed 3 Dec 2013.

  79. He Y-L, Yamaguchi M, Ito H, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2010;48(9):582–95.

    PubMed  CAS  Google Scholar 

  80. Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009;49(1):39–49.

    PubMed  Google Scholar 

  81. He Y-L, Ito H, Yamaguchi M, et al. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2012;50(4):237–47.

    PubMed  CAS  Google Scholar 

  82. He Y-L, Sabo R, Campestrini J, et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol. 2008;65(3):338–46.

    PubMed Central  PubMed  CAS  Google Scholar 

  83. He Y-L, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin. 2009;25(5):1265–72.

    PubMed  CAS  Google Scholar 

  84. Serra D, He Y-L, Bullock J, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2008;46(7):349–64.

    PubMed  CAS  Google Scholar 

  85. Yamaguchi M, Saji T, Mita S, et al. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2013;51(8):641–51.

    PubMed  CAS  Google Scholar 

  86. He Y-L, Sabo R, Riviere G-J, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007;23(5):1131–8.

    PubMed  CAS  Google Scholar 

  87. He Y-L, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. 2008;48(1):85–95.

    PubMed  CAS  Google Scholar 

  88. He Y-L, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol. 2007;47(8):998–1004.

    PubMed  CAS  Google Scholar 

  89. Ayalasomayajula SP, Dole K, He Y-L, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin. 2007;23(12):2913–20.

    PubMed  CAS  Google Scholar 

  90. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38(6):423–8.

    PubMed  CAS  Google Scholar 

  91. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905–9.

    PubMed  CAS  Google Scholar 

  92. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25(4):435–41.

    PubMed  Google Scholar 

  93. Kim NH, Sung Y-A, Ahn CW, et al. Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy [abstract no. 1154-P]. Diabetes. 2012;61(Suppl 1):A297.

    Google Scholar 

  94. Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(8):737–44.

    PubMed  CAS  Google Scholar 

  95. Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes. 2010;1(1):19–26.

    PubMed Central  PubMed  Google Scholar 

  96. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009;41(5):368–73.

    PubMed  CAS  Google Scholar 

  97. Jeon HJ, Oh TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J. 2011;35(5):529–35.

    PubMed Central  PubMed  Google Scholar 

  98. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial—a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11(10):978–86.

    PubMed  CAS  Google Scholar 

  99. Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;89(3):216–23.

    PubMed  CAS  Google Scholar 

  100. Lukashevich V, Prato SD, Araga M, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2013. doi:10.1111/dom.12229.

    Google Scholar 

  101. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148–55.

    PubMed  CAS  Google Scholar 

  102. Kothny W, Foley J, Kozlovski P, et al. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(3):252–7.

    PubMed  CAS  Google Scholar 

  103. Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382(9890):409–16.

    PubMed  CAS  Google Scholar 

  104. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804–12.

    PubMed  CAS  Google Scholar 

  105. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther. 2012;3:8.

    PubMed Central  PubMed  Google Scholar 

  106. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–9.

    PubMed  CAS  Google Scholar 

  107. Bolli G, Dotta F, Colin L, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11(6):589–95.

    PubMed  CAS  Google Scholar 

  108. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42(9):663–9.

    PubMed  CAS  Google Scholar 

  109. Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40(6):427–30.

    PubMed  CAS  Google Scholar 

  110. Kozlovski P, Foley J, Shao Q, et al. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes. 2013;4(4):151–6.

    PubMed Central  PubMed  Google Scholar 

  111. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947–54.

    PubMed  CAS  Google Scholar 

  112. Kothny W, Shao Q, Groop P-H, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14(11):1032–9.

    PubMed  CAS  Google Scholar 

  113. Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J. 2011;58(11):979–87.

    PubMed  CAS  Google Scholar 

  114. Lukashevich V, Schweizer A, Foley JE, et al. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 2013;9:21–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  115. Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67(10):947–56.

    PubMed  CAS  Google Scholar 

  116. Blüher M, Kurz I, Dannenmaier S, et al. Efficacy and safety of vildagliptin in clinical practice: results of the PROVIL-study. World J Diabetes. 2012;3(9):161–9.

    PubMed Central  PubMed  Google Scholar 

  117. Bringer J, Attali C, Simon D, et al. Interim results of the post-marketing survey of vildagliptin in France [abstract no. PDB13]. Value Health. 2012;15(7):A495.

    Google Scholar 

  118. Al-Arouj M, Hassoun AAK, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67(10):957–63.

    PubMed  CAS  Google Scholar 

  119. Halimi S, Levy M, Huet D, et al. Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: insights from the VERDI Study. Diabetes Ther. 2013;4(2):385–98.

    PubMed Central  PubMed  Google Scholar 

  120. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367–74.

    PubMed  CAS  Google Scholar 

  121. Shete A, Shaikh A, Nayeem KJ, et al. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes. 2013;4(6):358–64.

    PubMed Central  PubMed  Google Scholar 

  122. Hanif W, Malik W, Hassanein M, et al. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. Curr Med Res Opin. 2013;29(7):807–11.

    PubMed  CAS  Google Scholar 

  123. Schweizer A, Dejager S, Foley JE, et al. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011;7:49–57.

    PubMed Central  PubMed  Google Scholar 

  124. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485–94.

    PubMed  CAS  Google Scholar 

  125. Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab. 2010;12(6):495–509.

    PubMed  CAS  Google Scholar 

  126. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516–23.

    PubMed Central  PubMed  CAS  Google Scholar 

  127. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):38–47.

    PubMed  CAS  Google Scholar 

  128. Schweizer A, Dejager S, Foley JE, et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13(1):55–64.

    PubMed  CAS  Google Scholar 

  129. Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012;37(4):386–98.

    PubMed  CAS  Google Scholar 

  130. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther. 2011;2(2):51–66.

    PubMed Central  PubMed  CAS  Google Scholar 

  131. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  132. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.

    PubMed Central  PubMed  CAS  Google Scholar 

  133. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36 Suppl 1:S11–66.

  134. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125(3):7–20.

    PubMed  Google Scholar 

  135. Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339–48.

    PubMed Central  PubMed  CAS  Google Scholar 

  136. Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract. 2011;39(1):7–21.

    Google Scholar 

  137. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017–22.

    PubMed  CAS  Google Scholar 

  138. Charbonnel B, Schweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract. 2013;41(2):93–107.

    Google Scholar 

  139. European Medicines Agency. Januvia (sitagliptin): EU summary of product characteristics. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000722/human_med_000865.jsp&mid=WC0b01ac058001d124. Accessed 28 Jan 2014.

  140. European Medicines Agency. Onglyza (saxaliptin): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf. Accessed 28 Jan 2014.

  141. Schweizer A, Foley JE, Kothny W, et al. Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin. Vasc Health Risk Manag. 2013;9:57–64.

    PubMed Central  PubMed  CAS  Google Scholar 

  142. Pan C, Wang X. Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Manag. 2013;9:247–57.

    PubMed Central  PubMed  CAS  Google Scholar 

  143. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Intern Med. 2013;173(7):534–9.

    PubMed  CAS  Google Scholar 

  144. Faillie JL, Babai S, Crepin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2013. doi:10.1007/s00592-013-0544-0.

    PubMed  Google Scholar 

  145. Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12(4):545–57.

    PubMed  CAS  Google Scholar 

  146. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.

    PubMed  CAS  Google Scholar 

  147. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57–64.

    PubMed  CAS  Google Scholar 

  148. Gokhale M, Sturmer T, Gray C, et al. Dipeptidyl peptidase 4 inhibitors and comparative pancreatic cancer risk [abstract no. 111-LB]. In: 73rd Scientific Sessions of the American Diabetes Association; 21–25 Jun 2013; Chicago (IL).

  149. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609–29.

    PubMed  CAS  Google Scholar 

  150. Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25(2):225–31.

    PubMed  CAS  Google Scholar 

  151. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14:1123–8.

    Google Scholar 

  152. European Medicines Agency. Assessment report for GLP-1 based therapies. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/08/WC500147026.pdf. Accessed 20 Nov 2013.

  153. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    PubMed  CAS  Google Scholar 

  154. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

    PubMed  CAS  Google Scholar 

  155. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983–9 e7.

    Google Scholar 

  156. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10(4):289–301.

    PubMed  Google Scholar 

  157. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–98.

    PubMed  CAS  Google Scholar 

  158. Hatzikou M, Rombopoulos G, Yfantopoulos J. Economic evaluation of vildagliptin compared to glimepiride as add-on to metformin for the treatment of diabetes mellitus type 2 patients in Greece [abstract no. PDB43]. Value Health. 2012;15(7):A501.

    Google Scholar 

  159. Calado F, Gruenberger JB, Silva-Nunes J, et al. Cost-effectiveness of vildagliptin compared to generic sulphonylureas added on to metformin from the Portuguese societal perspective [abstract no. PDB45]. Value Health. 2012;15(7):A501.

    Google Scholar 

  160. Chen W, Zhu J. Economic evaluation of vildagliptin as add-on therapy to metformin in diabetes mellitus treatment in China [abstract no. PDB28]. Value Health. 2012;15(7):A664.

    Google Scholar 

  161. Genovese S, Tedeschi D. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. Adv Ther. 2013;30(2):152–64.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Additional information

The manuscript was reviewed by: E. Mannucci, Diabetes Agency, Careggi Teaching Hospital, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; G. Paolisso, Department of Geriatric Medicine and Metabolic Diseases, Second University of Naples, Naples, Italy; A.J. Scheen, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman, Liège, Belgium; E. Standl, Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M. Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74, 587–610 (2014). https://doi.org/10.1007/s40265-014-0199-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0199-3

Keywords

Search

Navigation